These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22160862)

  • 21. Glucose lowering and cardiovascular disease: what do we know and what should we do?
    Cheng AY; Leiter LA
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
    Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
    Eur J Prev Cardiol; 2013 Apr; 20(2):209-17. PubMed ID: 22345692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing diabetes management through glucose profiling: a case-based approach.
    Streja DA
    Prim Care Diabetes; 2008 Dec; 2(4):167-73. PubMed ID: 18786873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus.
    Swidan SZ; Montgomery PA
    Pharmacotherapy; 1998; 18(5):961-72. PubMed ID: 9758308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes.
    Yu PC; Bosnyak Z; Ceriello A
    Diabetes Res Clin Pract; 2010 Jul; 89(1):1-9. PubMed ID: 20494468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Glycemic targets and cardiovascular morbi-mortality].
    Bordier L; Bauduceau B
    Presse Med; 2013 May; 42(5):855-60. PubMed ID: 23286961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating diabetes today with gliclazide MR: a matter of numbers.
    Avogaro A
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():14-9. PubMed ID: 22118706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes.
    Lipska KJ; Krumholz H; Soones T; Lee SJ
    JAMA; 2016 Mar; 315(10):1034-45. PubMed ID: 26954412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.
    Reaven PD; Moritz TE; Schwenke DC; Anderson RJ; Criqui M; Detrano R; Emanuele N; Kayshap M; Marks J; Mudaliar S; Harsha Rao R; Shah JH; Goldman S; Reda DJ; McCarren M; Abraira C; Duckworth W;
    Diabetes; 2009 Nov; 58(11):2642-8. PubMed ID: 19651816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus.
    Kapoor K; George P; Miller M
    Cardiology; 2016; 135(2):108-26. PubMed ID: 27299864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intensive glucose control in type 2 diabetes is beneficial].
    Nilsson PM; Attvall S
    Lakartidningen; 2009 Sep 2-8; 106(36):2198. PubMed ID: 19817174
    [No Abstract]   [Full Text] [Related]  

  • 36. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.
    Zoungas S; Chalmers J; Ninomiya T; Li Q; Cooper ME; Colagiuri S; Fulcher G; de Galan BE; Harrap S; Hamet P; Heller S; MacMahon S; Marre M; Poulter N; Travert F; Patel A; Neal B; Woodward M;
    Diabetologia; 2012 Mar; 55(3):636-43. PubMed ID: 22186981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
    Stettler C; Allemann S; Jüni P; Cull CA; Holman RR; Egger M; Krähenbühl S; Diem P
    Am Heart J; 2006 Jul; 152(1):27-38. PubMed ID: 16824829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of Hyperglycaemia, Hypoglycaemia, and Glucose Variability to Atherosclerotic Disease in Type 2 Diabetes.
    Magri CJ; Mintoff D; Camilleri L; Xuereb RG; Galea J; Fava S
    J Diabetes Res; 2018; 2018():7464320. PubMed ID: 30140707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].
    Lambiel J; Fumeaux T
    Rev Med Suisse; 2008 Aug; 4(166):1734. PubMed ID: 18777740
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
    Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
    Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.